Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 14

1.

Population pharmacokinetic modeling for enterohepatic recirculation in Rhesus monkey.

Shou M, Lu W, Kari PH, Xiang C, Liang Y, Lu P, Cui D, Emary WB, Michel KB, Adelsberger JK, Brunner JE, Rodrigues AD.

Eur J Pharm Sci. 2005 Oct;26(2):151-61.

PMID:
16085400
2.

Influence of beta-adrenoceptor antagonists on the pharmacokinetics of rizatriptan, a 5-HT1B/1D agonist: differential effects of propranolol, nadolol and metoprolol.

Goldberg MR, Sciberras D, De Smet M, Lowry R, Tomasko L, Lee Y, Olah TV, Zhao J, Vyas KP, Halpin R, Kari PH, James I.

Br J Clin Pharmacol. 2001 Jul;52(1):69-76.

3.

Metabolites of caspofungin acetate, a potent antifungal agent, in human plasma and urine.

Balani SK, Xu X, Arison BH, Silva MV, Gries A, DeLuna FA, Cui D, Kari PH, Ly T, Hop CE, Singh R, Wallace MA, Dean DC, Lin JH, Pearson PG, Baillie TA.

Drug Metab Dispos. 2000 Nov;28(11):1274-8.

PMID:
11038152
4.

Metabolism of A dopamine D(4)-selective antagonist in rat, monkey, and humans: formation of A novel mercapturic acid adduct.

Zhang KE, Kari PH, Davis MR, Doss G, Baillie TA, Vyas KP.

Drug Metab Dispos. 2000 Jun;28(6):633-42.

PMID:
10820134
5.

Biotransformation of lovastatin. V. Species differences in in vivo metabolite profiles of mouse, rat, dog, and human.

Halpin RA, Ulm EH, Till AE, Kari PH, Vyas KP, Hunninghake DB, Duggan DE.

Drug Metab Dispos. 1993 Nov-Dec;21(6):1003-11.

PMID:
7905377
6.

In vivo and in vitro metabolism studies on a class III antiarrhythmic agent.

Vickers S, Duncan CA, Kari PH, Homnick CF, Elliott JM, Pitzenberger SM, Hichens M, Vyas KP.

Drug Metab Dispos. 1993 May-Jun;21(3):467-73.

PMID:
8100503
7.
8.

HMG-CoA reductase inhibitor-induced myopathy in the rat: cyclosporine A interaction and mechanism studies.

Smith PF, Eydelloth RS, Grossman SJ, Stubbs RJ, Schwartz MS, Germershausen JI, Vyas KP, Kari PH, MacDonald JS.

J Pharmacol Exp Ther. 1991 Jun;257(3):1225-35.

PMID:
1904494
9.

Metabolism of antiparkinson agent dopazinol by rat liver microsomes.

Vyas KP, Kari PH, Ramjit HG, Pitzenberger SM, Hichens M.

Drug Metab Dispos. 1990 Nov-Dec;18(6):1025-30.

PMID:
1981508
10.

In vitro and in vivo biotransformation of simvastatin, an inhibitor of HMG CoA reductase.

Vickers S, Duncan CA, Vyas KP, Kari PH, Arison B, Prakash SR, Ramjit HG, Pitzenberger SM, Stokker G, Duggan DE.

Drug Metab Dispos. 1990 Jul-Aug;18(4):476-83.

PMID:
1976071
11.
12.

Biotransformation of lovastatin. I. Structure elucidation of in vitro and in vivo metabolites in the rat and mouse.

Vyas KP, Kari PH, Pitzenberger SM, Halpin RA, Ramjit HG, Arison B, Murphy JS, Hoffman WF, Schwartz MS, Ulm EH, et al.

Drug Metab Dispos. 1990 Mar-Apr;18(2):203-11.

PMID:
1971574
13.

Regioselectivity and stereoselectivity in the metabolism of HMG-CoA reductase inhibitors.

Vyas KP, Kari PH, Pitzenberger SM.

Biochem Biophys Res Commun. 1990 Feb 14;166(3):1155-62.

PMID:
2306236
14.

Supplemental Content

Support Center